Hypereosinophilic Syndrome: Contemporary Approaches to Molecular-Genetic Diagnostics and Gene-Engineered Biologic Therapy
Open Access
- 21 March 2025
- journal article
- Published by National Research Mordovia State University MRSU in Medicine and Biotechnology
- Vol. 1 (1) , 13-23
Abstract
Introduction. In recent years, there has been a growing interest among researchers in conditions associated with hypereosinophilia and the therapeutic potential of genetically engineered biological agents. Hypereosinophilic syndrome remains an insufficiently studied issue encompassing a spectrum of disorders characterized by persistent eosinophilia and eosinophilic involvement of internal organs. The aim of this study is to systematize scientific literature data on novel diagnostic and treatment approaches for hypereosinophilic syndrome.Materials and methods. A comprehensive analysis was conducted on research publications selected based on the keywords “hypereosinophilia”, “hypereosinophilic syndrome”, “molecular-genetic studies”, “idiopathic hypereosinophilic syndrome” and “monoclonal antibody” from a cohort of full-text articles available in the electronic scientific databases eLibrary, PubMed, and Scopus between 2005 and 2024.Results. The hypereosinophilic syndrome is a rare condition, with a limited number of scientific observations available in the literature, primarily consisting of analyses of individual clinical cases. Data on the prevalence of hypereosinophilic syndrome in the pediatric population are extremely scarce. The causes of the syndrome are variable, and the clinical presentation is polymorphic, complicating the diagnostic process. Molecular-genetic research, including the detection of tyrosine kinase gene mutation types, contributes to solving this issue. First-line treatment involves glucocorticosteroids. It has been shown that genetically engineered biological agents are more effective in the treatment of primary hypereosinophilic syndrome, with their pathogenetically justified use associated with therapeutic progress.Discussion and conclusion. The hypereosinophilic syndrome is more commonly observed in young and middle-aged patients. Diagnostic criteria include persistent hypereosinophilia with organ damage or dysfunction, as well as the exclusion of other myeloid neoplasms. The use of genetically engineered biologic agents enables overcoming refractoriness, reducing the need for glucocorticosteroids, and preventing the development of drug-related complications.Keywords
This publication has 46 references indexed in Scilit:
- World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2024
- Updates on eosinophilic disordersVirchows Archiv, 2022
- Idiopathic hypereosinophilic syndrome—diagnosis and treatmentAllergo Journal International, 2022
- The hypereosinophilic syndrome - an unusual cause of myocarditis and cardioembolic strokesThe American Journal of the Medical Sciences, 2022
- World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2021
- Eosinophils in skin diseasesSeminars in Immunopathology, 2021
- Benralizumab in Severe and Refractory PDGFRA-Negative Hypereosinophilic SyndromeJournal of Clinical Immunology, 2021
- Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumabRespirology Case Reports, 2020
- A population‐based study of chronic eosinophilic leukemia‐not otherwise specified in the United StatesAmerican Journal of Hematology, 2020
- Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genesAmerican Journal of Hematology, 2020